Benzinga | Nov 3, 2021 09:21AM EDT

RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $250

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $246 to $250.